Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index

被引:298
作者
Revicki, DA
Rentz, AM
Dubois, D
Kahrilas, P
Stanghellini, V
Talley, NJ
Tack, J
机构
[1] MEDTAP Int, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] Johnson & Johnson Pharmaceut Res & Dev LLC, Beerse, Belgium
[3] Northwestern Univ, Div Gastroenterol, Chicago, IL 60611 USA
[4] Univ Bologna, Dept Internal Med & Gastroenterol, Bologna, Italy
[5] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[6] Univ Louvain, Dept Gastroenterol, Louvain, Belgium
关键词
D O I
10.1046/j.1365-2036.2003.01612.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Patient-based symptom assessments are necessary to evaluate the effectiveness of medical treatments for gastroparesis. Aim: To summarize the development and measurement qualities of the Gastroparesis Cardinal Symptom Index (GCSI), a new measure of gastroparesis-related symptoms. Methods: The GCSI was based on reviews of the medical literature, clinician interviews and patient focus groups. The measurement qualities (i.e. reliability, validity) of the GCSI were examined in 169 gastroparesis patients. Patients were recruited from seven clinical centres in the USA to participate in this observational study. Patients completed the GCSI, SF-36 Health Survey and disability day questions at a baseline visit and again after 8 weeks. Clinicians independently rated the severity of the patients' symptoms, and both clinicians and patients rated the change in gastroparesis-related symptoms over the 8-week study. Results: The GCSI consists of three sub-scales: post-prandial fullness/early satiety, nausea/vomiting and bloating. The internal consistency reliability was 0.84 and the test-re-test reliability was 0.76 for the GCSI total score. Significant relationships were observed between the clinician-assessed symptom severity and the GCSI total score, and significant associations were found between the GCSI scores and SF-36 physical and mental component summary scores and restricted activity and bed disability days. Patients with greater symptom severity, as rated by clinicians, reported greater symptom severity on the GCSI. The GCSI total scores were responsive to changes in overall gastroparesis symptoms as assessed by clinicians (P = 0.0002) and patients (P = 0.002). Conclusion: The findings of this study indicate that the GCSI is a reliable and valid instrument for measuring the symptom severity in patients with gastroparesis.
引用
收藏
页码:141 / 150
页数:10
相关论文
共 34 条
[1]  
Bityutskiy LP, 1997, AM J GASTROENTEROL, V92, P1501
[2]   DEPRESSION, DISABILITY DAYS, AND DAYS LOST FROM WORK IN A PROSPECTIVE EPIDEMIOLOGIC SURVEY [J].
BROADHEAD, WE ;
BLAZER, DG ;
GEORGE, LK ;
CHIU, KT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (19) :2524-2528
[3]   Prevalence of gastrointestinal symptoms associated with diabetes mellitus - A population-based survey of 15000 adults [J].
Bytzer, P ;
Talley, NJ ;
Leemon, M ;
Young, LJ ;
Jones, MP ;
Horowitz, M .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (16) :1989-1996
[4]  
Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127
[5]  
COULIE B, 2002, DIG DIS WEEK ANN C S
[6]   Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis [J].
Farup, CE ;
Leidy, NK ;
Murray, M ;
Williams, GR ;
Helbers, L ;
Quigley, EMM .
DIABETES CARE, 1998, 21 (10) :1699-1706
[7]  
Frank L, 2000, DIGEST DIS SCI, V45, P809, DOI 10.1023/A:1005468332122
[8]   Interpreting treatment effects in randomised trials [J].
Guyatt, GH ;
Juniper, EF ;
Walter, SD ;
Griffith, LE ;
Goldstein, RS .
BRITISH MEDICAL JOURNAL, 1998, 316 (7132) :690-693
[9]   Methods to explain the clinical significance of health status measures [J].
Guyatt, GH ;
Osoba, D ;
Wu, AW ;
Wyrwich, KW ;
Norman, GR .
MAYO CLINIC PROCEEDINGS, 2002, 77 (04) :371-383
[10]  
Hays RD, 1998, OX MED PUBL, P169